The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or ...

Trial finds CAR‑T approach shows minimal CRS and no neurotoxicity or prolonged cytopenia, enabling safer treatment for older, ...

At a live Case-Based Roundtable event during the 2025 American Society of Hematology (ASH) annual meeting, Joshua Richter, MD, discussed the evolving role of selinexor (Xpovio) in ...

AI begins transforming precision oncology, speeding drug target discovery with AlphaFold and cutting clinical trial paperwork from months to days.

Neoadjuvant pembrolizumab (3 doses) in stage I–III disease yielded a 71% pCR rate and only one melanoma-specific survival event at 3 years post-resection. Experts discuss the SWOG S1512 trial of ...

This marks the first time a bispecific ADC has demonstrated a dual benefit in both PFS and OS within a phase 3 trial for TNBC. While standard chemotherapy options offer limited durability in the ...

In the closing segment, Dr Shaheen reflects on unmet needs and future directions for patients with advanced pancreatic neuroendocrine tumors. She acknowledges that while treatment options have ...

Final overall survival data for PEACE-3 (NCT02194842) evaluating the combination of enzalutamide (Xtandi) and radium-223 ...

Anticipated findings from the LITESPARK-011 trial (NCT04586231) to be presented during the 2026 ASCO Genitourinary Cancers ...

In an interview with Targeted Oncology, Paolo Strati, MD, associate professor in the Department of Lymphoma/Myeloma in the ...

In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 ...